Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM97Q6T)

Drug Name

N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine Drug Info

Synonyms

CHEMBL233385; N-[[5-bromo-2-[(4-chlorophenyl)methoxy]phenyl]methyl]ethanamine; AC1NFZZ9; N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine; SCHEMBL5700011; ZINC8227211; BDBM50205773; AKOS002615028; MCULE-5007100183; Benzenemethanamine, 5-bromo-2-[(4-chlorophenyl)methoxy]-N-ethyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4716524
TTD Drug ID: DM97Q6T

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-C chemokine receptor type 5 (CCR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Maraviroc	DMTL94F	Human immunodeficiency virus infection	1C62	Approved	[2]
Vicriviroc	DMMTW9K	Human immunodeficiency virus infection	1C62	Phase 3	[3]
PRO-140	DMD1FTP	Human immunodeficiency virus infection	1C62	Phase 3	[4]
E-913	DMUHS5Q	Human immunodeficiency virus infection	1C62	Phase 3	[5]
PRO 140	DMCGK6X	Human immunodeficiency virus-1 infection	1C62	Phase 2/3	[6]
INCB9471	DMMWC6F	Infectious disease	1A00-CA43.1	Phase 2a	[5]
Cenicriviroc	DM4V8WF	Human immunodeficiency virus infection	1C62	Phase 2	[7]
BMS-813160	DMKY638	Diabetic nephropathy	GB61.Z	Phase 2	[8]
SB-728-T	DMRWE5D	Human immunodeficiency virus infection	1C62	Phase 2	[9]
PF-232798	DM8T6KQ	Human immunodeficiency virus infection	1C62	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 5 (CCR5)	TT2CEJG	CCR5_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1883-7.
2	Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
3	HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
4	Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
5	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
6	The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
7	The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
8	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
9	Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
10	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.